Twist Bioscience COO sells shares to cover taxes

Twist Bioscience Corp's President and COO, Patrick John Finn, reported an automatic sale of common stock tied to equity compensation.

Rhea-AI Filing Summary

Twist Bioscience Corp's President and COO, Patrick John Finn, reported an automatic sale of common stock tied to equity compensation. On 02/03/2026, 2,705 shares of common stock were sold at $46.576 per share to cover tax withholding obligations from vesting restricted stock units. After this mandated "sell to cover" transaction under the company’s equity incentive plans, Finn beneficially owned 307,788 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 2,705 shares

Net Sell 1 txn

Insider Finn Patrick John

Role President and COO

Sold 2,705 shs ($126K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,705	$46.576	$126K

Holdings After Transaction: Common Stock — 307,788 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Twist Bioscience (TWST) insider Patrick John Finn report in this Form 4?

Patrick John Finn, President and COO of Twist Bioscience, reported selling 2,705 common shares. The sale occurred on 02/03/2026 at $46.576 per share and was linked to tax withholding from vesting restricted stock units under the company’s equity incentive plans.

Was the Twist Bioscience (TWST) insider stock sale a discretionary trade?

No, the sale was not discretionary. The 2,705 shares were sold automatically to cover tax withholding obligations arising from vesting restricted stock units, as required by Twist Bioscience’s equity incentive plan "sell to cover" election, rather than a voluntary open-market decision.

How many Twist Bioscience (TWST) shares did Patrick John Finn sell and at what price?

Patrick John Finn sold 2,705 shares of Twist Bioscience common stock. The transaction took place on 02/03/2026 at a price of $46.576 per share, according to the Form 4 filing and its accompanying explanation of responses footnote.

How many Twist Bioscience (TWST) shares does Patrick John Finn own after this transaction?

Following the 2,705-share sale for tax withholding on 02/03/2026, Patrick John Finn beneficially owned 307,788 shares of Twist Bioscience common stock. The Form 4 indicates these holdings are reported as directly owned after the automatic "sell to cover" transaction.

What role does Patrick John Finn hold at Twist Bioscience (TWST)?

Patrick John Finn serves as President and Chief Operating Officer of Twist Bioscience. His position is identified in the Form 4, where he is listed as an officer rather than a director or 10% owner, in connection with the reported equity-related stock sale.

Why did Twist Bioscience (TWST) shares get sold in connection with restricted stock units?

Shares were sold to satisfy tax withholding generated when restricted stock units vested. Twist Bioscience’s equity incentive plans require funding this withholding through a "sell to cover" transaction, causing 2,705 shares to be automatically sold instead of the insider paying taxes in cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S		2,705(1)	D	$46.576	307,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.